RecruitingPhase 1NCT04830137

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

Sponsor

Nurix Therapeutics, Inc.

Enrollment

248 participants

Start Date

May 5, 2021

Study Type

INTERVENTIONAL

Conditions

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new drug called NX-2127 in adults with B-cell blood cancers (such as B-cell lymphoma or chronic lymphocytic leukemia) that have come back after prior treatment or stopped responding to it. NX-2127 works by targeting two proteins that help cancer cells survive and grow. **You may be eligible if...** - You are 18 years or older - You have a B-cell blood cancer (such as lymphoma, CLL, or primary CNS lymphoma) that has returned or stopped responding to prior therapies - Your cancer is measurable on scans or lab tests - You are in reasonably good health **You may NOT be eligible if...** - You have certain very aggressive or genetically complex subtypes of lymphoma (such as prolymphocytic leukemia or MCL with a TP53 mutation) - Your overall health status is too poor - You have severe liver, kidney, or bone marrow problems Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNX-2127

Oral NX-2127

Locations(16)

City of Hope

Duarte, California, United States

University of California Irvine

Orange, California, United States

University of California San Francisco Medical Center

San Francisco, California, United States

Sarah Cannon Research Institute at Colorado Blood Cancer Institute

Denver, Colorado, United States

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States

Sarah Cannon Research Institute at Florida Cancer Specialists

Sarasota, Florida, United States

The University of Chicago Medical Center

Chicago, Illinois, United States

National Institutes of Health Clinical Center

Bethesda, Maryland, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

University of Cincinnati Medical Center

Cincinnati, Ohio, United States

OSU Wexner Medical Center

Columbus, Ohio, United States

Tennessee Oncology

Nashville, Tennessee, United States

Baylor University Medical Center

Dallas, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, United States

Swedish Cancer Institute

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04830137

Related Trials

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

NCT010873331 location

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

NCT072053152 locations

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT057241211 location

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

NCT0513102262 locations

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

NCT0722150020 locations